To our knowledge, this study is the largest cohort study to investigate the value of baseline PNI, baseline BMI, and pretreatment BMI trend in predicting outcomes to anti-PD-1/L1 or anti-CTLA4 therapies (or both) in head and neck cancer patients. The gene discussed is CTLA4; the disease is head and neck cancer.